Home › Funds › Lynx1 Capital Management LP › IKT
Lynx1 Capital Management LP position in IKT
INHIBIKASE THERAPEUTICS INC · Health Care
Lynx1 Capital Management LP reported holding 20,000 shares of IKT (INHIBIKASE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1K, representing 0.00% of its reported portfolio and ranking #31 among its reported holdings. Lynx1 Capital Management LP has disclosed IKT holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Lynx1 Capital Management LP's IKT position evolved
Lynx1 Capital Management LP first disclosed a stake in IKT in Q2 2026 at 20,000 shares (US$41K). Across 2 filings, Lynx1 Capital Management LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 20,000 shares valued at US$1K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 20.00K | $40.60K | New |
| Q3 2026 | 20.00K | $1.20K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IKT and 13F data
IKT (INHIBIKASE THERAPEUTICS INC) is a Health Care company. 63 other funds we track also report a position in IKT — the largest reported positions include Sands Capital Alternatives, LLC (US$26.8M), Soleus Capital Management, L.P. (US$23.1M), Trails Edge Capital Partners, LP (US$18.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IKT
- Sands Capital Alternatives, LLC 13.02M sh · $26.82M · Q3 2026
- Soleus Capital Management, L.P. 11.22M sh · $23.07M · Q3 2026
- Trails Edge Capital Partners, LP 9.11M sh · $18.72M · Q3 2026
- Fairmount Funds Management LLC 8.62M sh · $17.72M · Q3 2026
- ADAR1 Capital Management, LLC 5.71M sh · $11.73M · Q3 2026
- Commodore Capital LP 5.40M sh · $11.09M · Q3 2026
- Saturn V Capital Management LP 3.87M sh · $7.95M · Q3 2026
- Kalehua Capital Management LLC 3.82M sh · $7.85M · Q3 2026
- Spruce Street Capital LP 3.58M sh · $7.36M · Q3 2026
- Squadron Capital Management LLC 2.00M sh · $4.11M · Q3 2026
- Tyro Capital Management LLC 1.37M sh · $2.81M · Q3 2026
- Kennondale Capital Management LLC 721.96K sh · $1.48M · Q3 2026
More on Lynx1 Capital Management LP
FAQ
How long has Lynx1 Capital Management LP held IKT?
Lynx1 Capital Management LP has disclosed IKT holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Lynx1 Capital Management LP's current position in IKT?
As of Q3 2026, Lynx1 Capital Management LP holds 20.00K shares of IKT (INHIBIKASE THERAPEUTICS INC), valued at $1.20K, representing 0.00% of its reported portfolio and ranking #31.
Has Lynx1 Capital Management LP been buying or selling IKT?
In the latest 13F filing (Q3 2026), Lynx1 Capital Management LP held unchanged its position in IKT.
Which other funds hold IKT?
Other major institutional holders of IKT include Sands Capital Alternatives, LLC, Soleus Capital Management, L.P., Trails Edge Capital Partners, LP, among 63 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.